MedTrace Logo

LMY-920 for Treatment of Relapsed or Refractory Myeloma

NCT05546723 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-10-18

No results posted yet for this study

Summary

Since CAR-T cell treatment of refractory myeloma has shown success, based on preclinical data, we posit that CAR-T cells expressing B-cell activating factor (BAFF) can become another strategy to treat refractory myeloma, even after relapse following BCMA targeting CAR-T cell treatment. This will be phase 1 study of BAFF ligand CAR-T cells in relapsed and refractory myeloma.

Conditions

  • Multiple Myeloma, Refractory
  • Multiple Myeloma in Relapse

Interventions

BIOLOGICAL

Autologous CAR-T cell therapy expressing the BAFF-ligand.

LMY-920

Sponsors & Collaborators

  • The Cleveland Clinic

    collaborator OTHER

  • Case Western Reserve University

    collaborator OTHER

  • Luminary Therapeutics

    lead INDUSTRY

Principal Investigators

  • Leland Metheny, MD · University Hospitals Seidman Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-13
Primary Completion
2025-07-31
Completion
2025-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05546723 on ClinicalTrials.gov